| Name | Title | Contact Details |
|---|
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.
The Dunn Group is a Totowa, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Help control your eye pressure and possibly reduce your need for Glaucoma medication with the Hydrus® Microstent.
BlissCo Cannabis Corp. (CSE: BLIS) (FRA: GQ4B) is an ACMPR licensed producer and future distributor of ultra-premium cannabis. The company sits at the heart of an international ecosystem and is focused on the success of its domestic and global partnerships. BlissCo leverages the latest technology and is continuously developing its network of top-tier industry experts to drive the success of its brand and channels, moving premium Canadian cannabis to local and international markets. BlissCo is backed by an experienced team that is deeply in tune and integrated with industry partners and BlissCo`s future patients and customers.